

**ESPS Peer-review Report**

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 10978

**Title:** The Emerging Roles of Cytokines from the SIBLING and SPARC Families in Pancreatic Cancer Progression and Metastasis

**Reviewer code:** 00030205

**Science editor:** Ma, Ya-Juan

**Date sent for review:** 2013-10-25 14:51

**Date reviewed:** 2013-11-29 21:31

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input checked="" type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of	<input type="checkbox"/> No records	
<input type="checkbox"/> Grade D (Fair)	language polishing	BPG Search:	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

**COMMENTS TO AUTHORS**

The review is well written and interesting. An additional information should be added to the introduction upon how the article will be disposed and the data presented. The section on Targeted therapies in pancreatic cancer may be subdivided according to different targeting mechanisms to increase clarity.

**ESPS Peer-review Report**

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 10978

**Title:** The Emerging Roles of Cytokines from the SIBLING and SPARC Families in Pancreatic Cancer Progression and Metastasis

**Reviewer code:** 02441392

**Science editor:** Ma, Ya-Juan

**Date sent for review:** 2013-10-25 14:51

**Date reviewed:** 2013-12-27 13:58

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input type="checkbox"/> Accept
<input type="checkbox"/> Grade B (Very good)	<input type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of language polishing	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)		<input type="checkbox"/> No records	<input type="checkbox"/> Major revision

**COMMENTS TO AUTHORS**

This review with numerous reports is focused on SIBLING family, osteopontin and SPARC family, osteonectin (ON) that control pancreatic cancer growth and metastasis. This is a well-written review and interesting. Therefore, this is worth publishing. However, the description of ON in the text is not clear. Major points. 1. The authors mainly described the antitumorigenic potential of ON in pancreatic cancer in section of Prominent roles in pancreatic cancer progression (pages 6 and 7). However, ON is suggested to be a strong marker of poor prognosis in section of Biomarker role for pancreatic cancer (page 8). Please explain this discrepancy in detail. Most pancreatic cancer cells and cell lines are ON negative (page 5, line 10), but the authors refer to some ON knockdown experiments in pancreatic cancer cell lines (pages 6 and 7). These descriptions seem to be inconsistent. 2. Median survival in ON (+) patients was decreased by 50% (15 months) as compared to ON (-) patients (30 months) (page 8, lines 12-14). In addition, the 5-year survival rate in patients with a low ON mRNA level was better (23%) as compared to those with high ON mRNA level (0%) (page 8, lines 19-21). However, median OS increased significantly in the group with high ON expression when compared to the low-ON group (17.8 vs 8.1 months) (page 9, lines 10 and 11). I cannot understand this discrepancy. Minor points. 1. At its first appearance in the text, an abbreviation should be spelled out. Page 3, line 6. "TGF-b" should read "transforming growth factor-beta (TGFβ)". Page 3, line 22. Please spell out "α-SMA". Page 5, line 25. Please spell out "ILK". 2. Please unify the abbreviations. For example, "MEK" and "Mek", "AP1" and "Ap-1". 3. Page 4, line 8. (A), (B), (C) and (D) are not needed. 4. Page 5, lines 2 and 3. What does "ECM of pancreatic cancer cell lines"



**Baishideng Publishing Group Co., Limited**

Flat C, 23/F., Lucky Plaza,  
315-321 Lockhart Road, Wan Chai, Hong Kong, China

---

mean?

**ESPS Peer-review Report**

**Name of Journal:** World Journal of Gastroenterology

**ESPS Manuscript NO:** 10978

**Title:** The Emerging Roles of Cytokines from the SIBLING and SPARC Families in Pancreatic Cancer Progression and Metastasis

**Reviewer code:** 02451547

**Science editor:** Ma, Ya-Juan

**Date sent for review:** 2013-10-25 14:51

**Date reviewed:** 2014-01-03 11:14

CLASSIFICATION	LANGUAGE EVALUATION	RECOMMENDATION	CONCLUSION
<input type="checkbox"/> Grade A (Excellent)	<input type="checkbox"/> Grade A: Priority Publishing	Google Search:	<input checked="" type="checkbox"/> Accept
<input checked="" type="checkbox"/> Grade B (Very good)	<input checked="" type="checkbox"/> Grade B: minor language polishing	<input type="checkbox"/> Existed	<input type="checkbox"/> High priority for publication
<input type="checkbox"/> Grade C (Good)	<input type="checkbox"/> Grade C: a great deal of	<input type="checkbox"/> No records	<input type="checkbox"/> Rejection
<input type="checkbox"/> Grade D (Fair)	language polishing	BPG Search:	<input type="checkbox"/> Minor revision
<input type="checkbox"/> Grade E (Poor)	<input type="checkbox"/> Grade D: rejected	<input type="checkbox"/> Existed	<input type="checkbox"/> Major revision
		<input type="checkbox"/> No records	

**COMMENTS TO AUTHORS**

This is a well-written and interest review, the authors reviewed the emerging roles of cytokines from the SIBLING and SPARC families in pancreatic cancer progression and metastasis comprehensively. This manuscript should be accepted. Minor revision: 1. In section of introduction: the first sentence, "Pancreatic cancer, the fourth leading cause of cancer", I guess a word is missing. It should be "Pancreatic cancer, the fourth leading cause of cancer death". 2. Some place showed "Phase III ...", and another is "phase III ...". Which one is correct.